Full Press Release Details
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room. Sepsis remains a leading cause of death in the U.S. Barriers to diagnosis lead to organ failure and higher mortality rates.
Hosted by Josh Casey, this episode features QuidelOrtho's Medical Science Liaison Chris Sanchez, MSN, RN, who brings to light diagnostic strategies necessary to support critically ill patients. Chris brings firsthand experience implementing diagnostic strategies as well as caring for critically ill patients.
Hosted by Josh Casey, this episode features QuidelOrtho's Medical Science Liaison Chris Sanchez, MSN, RN, who brings to light diagnostic strategies necessary to support critically ill patients. Chris brings firsthand experience implementing diagnostic strategies as well as caring for critically ill patients.
Key Insights:
• One in five adults and one in ten children who contract sepsis die or go into hospice care
• Delayed diagnosis and overuse of fluid resuscitation methods increase mortality rates
• Inability to distinguish between bacterial and viral infections handicaps clinicians in making the right treatment decisions
• Bacterial infections that go unrecognized may quickly escalate into sepsis
• Swift diagnosis can mitigate these challenges as well as the overuse of antibiotics
• Serial procalcitonin testing aids clinicians in identifying opportunities for antibiotic discontinuation or de-escalation
• Early testing presents opportunities for quick intervention as well as targeted treatment
The conversation illuminates how rapid, actionable diagnostic information can aid emergency medicine physicians in making time-critical decisions in the ER.
Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact: Juliet Cunningham Vice President, Investor Relations [email protected]
Media Contact: Stephanie Kleewein Senior Corporate Communication and PR Manager [email protected]